CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 27 K

LB filings
2025.08.14 12:44
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 27 K.

EPS: As of FY2025 Q2, the actual value is USD -0.78.

Financial Metrics Summary

Cash and Cash Equivalents

  • As of June 30, 2025, Clene Inc. reported cash and cash equivalents of $7.3 million, a decrease from $12.2 million as of December 31, 2024. The company expects that its resources, along with $1.9 million raised in equity and a $1.5 million increase in its convertible debt facility, will be sufficient to fund operations into the first quarter of 2026.

Research and Development Expenses

  • Research and development expenses were $3.5 million for the quarter ended June 30, 2025, compared to $4.2 million for the same period in 2024. The decrease was primarily due to reduced personnel expenses and stock-based compensation, offset by increased expenses related to the ALS clinical programs.

General and Administrative Expenses

  • General and administrative expenses were $2.4 million for the quarter ended June 30, 2025, down from $3.3 million for the same period in 2024. This decrease was mainly due to reduced personnel expenses, stock-based compensation, and legal fees, partially offset by increased finance and accounting fees.

Net Loss

  • Clene reported a net loss of $7.4 million, or $0.78 per share, for the quarter ended June 30, 2025, compared to a net loss of $6.8 million, or $1.06 per share, for the same period in 2024.

Total Other Expense

  • Total other expense was $1.6 million for the quarter ended June 30, 2025, compared to total other income of $0.6 million for the same period in 2024. This change was primarily due to non-cash losses on derivative liabilities and common stock warrant liabilities, and decreased interest income.

Outlook / Guidance

  • Clene plans to analyze neurofilament light data from its NIH-sponsored Early Access Protocol in the fourth quarter of 2025 and expects to submit a New Drug Application for CNM-Au8 in ALS by the end of 2025. The company anticipates that its current resources will fund operations into the first quarter of 2026.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.